Seres Therapeutics (MCRB) Operating Margin (2016 - 2026)
Seres Therapeutics' (MCRB) quarterly Operating Margin came in at 2890.35% in Q2 2026, up 50.51% quarter-over-quarter from 5839.94% in Q1 2026.
Powered by 
Analysis
Seres Therapeutics (MCRB) Operating Margin (2016 - 2026) Analysis & Trends
Seres Therapeutics has disclosed Operating Margin across 10 years of filings, most recently posting 2890.35% for Q2 2026.
- In Q2 2026, Operating Margin changed N/A year-over-year to 2890.35%; the TTM figure through Jun 2026 stood at 4462.77% (changed N/A YoY), while the FY2025 annual figure was 11910.14%, changed N/A from the prior year.
- Operating Margin came in at 2890.35% for Q2 2026 at Seres Therapeutics, up from 5839.94% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 39.16% in Q2 2023 to a low of 14382.58% in Q3 2023.
- Average Operating Margin over 4 years is 4852.2%, with a median of 4079.07% recorded in 2022.
- The largest YoY upside for Operating Margin was 524681 bps in 2023 against a maximum downside of 1266635 bps in 2023.
- Over 4 years, Operating Margin stood at 177.54% in 2022, then soared by 117 bps to 29.32% in 2023, then sank by 15187 bps to 4423.97% in 2025, then surged by 35 bps to 2890.35% in 2026.
- Per Business Quant data, the three most recent Operating Margin figures were 2890.35% in Q2 2026, 5839.94% in Q1 2026, and 4423.97% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.78 Bn | 192.79 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 179.92 Bn | 176.74 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 131.39 Bn | 123.54 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 81.91 Bn | 73.91 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 60.35 Bn | 55.17 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 53.67 Bn | 48.54 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.12 Bn | 29.81 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.92 Bn | 30.63 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.23 Bn | 29.23 Bn | 1.16 Mn | -25,380.93% |
| 10 | Seres Therapeutics | 49.70 Mn | 49.70 Mn | - | -2,890.35% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2,890.35% |
| Mar 31, 2026 | -5,839.94% |
| Dec 31, 2025 | -4,423.97% |
| Sep 30, 2025 | -6,403.70% |
| Dec 31, 2023 | 29.32% |
| Sep 30, 2023 | -14,382.58% |
| Jun 30, 2023 | 39.16% |
| Mar 31, 2023 | -13,518.77% |
| Dec 31, 2022 | -177.54% |
| Sep 30, 2022 | -1,716.23% |
| Jun 30, 2022 | -5,207.65% |
| Mar 31, 2022 | -3,734.16% |
| Dec 31, 2021 | -684.56% |
| Sep 30, 2021 | 53.98% |
| Jun 30, 2021 | -914.73% |
| Mar 31, 2021 | -617.80% |
| Dec 31, 2020 | -101.90% |
| Sep 30, 2020 | -2,116.80% |
| Jun 30, 2020 | -339.87% |
| Mar 31, 2020 | -240.47% |